Materiały źródłowe

• #1 Meningococcal Disease and the Vaccine: What College Students Need to Know – MN Dept. of Health

  https://www.health.state.mn.us/diseases/meningococcal/collegefact.html

  Anyone can get meningococcal disease, but first-year college students who live in dormitories or participate in sororities or fraternities are at increased risk and should get vaccinated. […] Vaccination is one of the most effective ways to prevent meningococcal disease. […] The meningococcal B vaccine (MenB) can be given to people aged 16-23 years. MenB vaccine is also recommended for people over age 10 years with certain high-risk conditions. […] It is important for students ages 16 to 23 who are planning to go to college or currently in college, to have a conversation with their health care provider about receiving the MenB vaccine. Anyone who has been fully vaccinated against MenB, would only need a single booster dose in the case of an outbreak on campus.

• #2

  https://www.meningitis.org/meningitis/vaccine-information-old-(1)/meningococcal-group-b-vaccine

  Meningococcal vaccines protect against disease caused by meningococcal bacteria. […] The vaccines that protect against meningococcal group B (MenB) are protein vaccines. These vaccines contain proteins found on the surface of the bacteria. […] The MenB vaccine provides protection against meningococcal disease, but doesn’t stop you from carrying the bacteria. […] Vaccination against meningococcal meningitis is also recommended if you’re travelling to areas at risk. […] Meningococcal vaccines have saved many lives. […] Vaccination with conjugate meningococcal vaccines also protects the wider population from meningococcal disease. […] Preventing meningococcal infections is key. […] Vaccination is the best way to protect against it.

• #3 Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination – PubMed

  https://pubmed.ncbi.nlm.nih.gov/33933528/

  4CMenB is a broadly protective vaccine against invasive meningococcal capsular group B disease (MenB IMD). […] Data from 7 countries provide evidence of effectiveness and impact across different healthcare settings and age-groups, including national/regional immunization programs, observational studies and outbreak control. […] At least 2 4CMenB doses reduced MenB IMD by 50%-100% in 2-month to 20-year-olds depending on length of follow-up. […] The substantial body of data demonstrating 4CMenB effectiveness and impact supports its use in IMD prevention. […] Direct protection via routine infant immunization with catch-up in young children and routine adolescent vaccination could be the preferred option for MenB disease control.

• #4 Meningococcal vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html

  BEXSERO: 4CMenB primary and booster vaccine schedules for individuals 2 months of age and older. […] Trumenba: primary and booster dose vaccine schedules for MenB-fHBP vaccine for individuals 10 years of age and older. […] Vaccines for the prevention of IMD that are authorized for use in Canada include: […] Serogroup B meningococcal vaccines […] Multicomponent meningococcal serogroup B vaccine (4CMenB) […] Bivalent factor-H binding protein meningococcal serogroup B vaccine (MenB-fHBP). […] High risk individuals: Men-C-ACYW and 4CMenB or MenB-fHBP vaccine is recommended for individuals at increased risk of IMD. […] Post-exposure management: in addition to chemoprophylaxis that is recommended for close contacts, if the serogroup is vaccine-preventable, immunoprophylaxis should also be considered, depending on the exposure history.

• #4 Meningococcal vaccines: Canadian Immunization Guide – Canada.ca

  https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-13-meningococcal-vaccine.html

  Vaccination or re-vaccination of certain close contacts should be considered in addition to chemoprophylaxis when the serogroup is vaccine preventable, as it may further reduce the risk of subsequent meningococcal disease. […] Meningococcal vaccine is contraindicated in persons with a history of anaphylaxis after previous administration of the vaccine and in persons with proven immediate or anaphylactic hypersensitivity to any component of the vaccine or its container.

• #5 Serogroup B Meningococcal Vaccine (MenB) – What You Need to Know – UF Health

  https://ufhealth.org/conditions-and-treatments/serogroup-b-meningococcal-vaccine-menb-what-you-need-to-know

  Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. A different meningococcal vaccine is available that can help protect against serogroups A, C, W, and Y. […] For best protection, more than 1 dose of a meningococcal B vaccine is needed. There are two meningococcal B vaccines available. The same vaccine must be used for all doses. […] Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease, including: People at risk because of a serogroup B meningococcal disease outbreak, Anyone whose spleen is damaged or has been removed, including people with sickle cell disease, Anyone with a rare immune system condition called „complement component deficiency,” Anyone taking a type of drug called a „complement inhibitor,” such as eculizumab (also called Soliris) or ravulizumab (also called Ultomiris), Microbiologists who routinely work with isolates of N. meningitidis. […] These vaccines may also be given to anyone 16 through 23 years old to provide short-term protection against most strains of serogroup B meningococcal disease, based on discussions between the patient and health care provider. The preferred age for vaccination is 16 through 18 years.

• #6

  https://www.healthychildren.org/English/safety-prevention/immunizations/Pages/MenB-Vaccines-What-You-Need-to-Know-VIS.aspx

  Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B. […] For best protection, more than 1 dose of a meningococcal B vaccine is needed. […] Meningococcal B vaccines are recommended for people 10 years or older who are at increased risk for serogroup B meningococcal disease, including: People at risk because of a serogroup B meningococcal disease outbreak. […] These vaccines may also be given to anyone 16 through 23 years old to provide short-term protection against most strains of serogroup B meningococcal disease; 16 through 18 years are the preferred ages for vaccination.

• #7 Ask The Experts About Vaccines: Meningococcal B | Immunize.org

  https://www.immunize.org/ask-experts/topic/menb/

  MenB is routinely recommended for these groups: […] People age 10 years and older who have functional or anatomic asplenia (including sickle cell disease) […] People age 10 years and older who have persistent complement component deficiency (an immune system disorder) or who take a complement inhibitor […] People age 10 years and older who are exposed during an outbreak caused by serogroup B […] Microbiologists who work with meningococcal isolates in a laboratory. […] For adolescents and young adults not otherwise at increased risk for meningococcal B disease, ACIP recommends that a MenB series may be administered to people 16 through 23 years of age (preferred age 16 through 18 years) on the basis of shared clinical decision-making. […] MenB vaccines were approved based on the serologic response to the vaccine.

• #7 Ask The Experts About Vaccines: Meningococcal B | Immunize.org

  https://www.immunize.org/ask-experts/topic/menb/

  Short term protection refers to the known duration of the antibody response. […] The first booster dose is recommended one year after completion of the primary series, with subsequent booster doses every 2-3 years as long as risk remains. […] ACIP recommends booster doses of MenB vaccines for people at increased risk of MenB disease. […] Booster doses should be administered to people in the following groups as long as increased risk remains: […] People with functional or anatomic asplenia, including sickle cell disease […] People with persistent complement component deficiency (an immune system disorder) […] People who take a complement inhibitor […] Microbiologists who routinely work with meningococcal isolates […] Previously vaccinated people who are at risk during a meningococcal B disease outbreak. […] Because protective antibody levels produced by the primary series begin to wane within 12 years, the first booster dose is recommended one year after completion of the primary series, with subsequent booster doses every 2-3 years as long as increased risk remains.

• #8 Vaccination Requirements | ULTOMIRIS® (ravulizumab-cwvz) | gMG

  https://ultomirishcp.com/gmg/vaccination-requirements

  Complete or update meningococcal vaccination (for serogroups A, C, W, Y and B) at least 2 weeks prior to administration of the first dose of ULTOMIRIS, per the current ACIP recommendations for patients receiving a complement inhibitor. […] If patients have not been vaccinated and ULTOMIRIS must be started right away, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. […] Your patient must receive both MenACWY and MenB vaccine series. The vaccines may be administered during the same visit but at different injection sites. […] To help reduce the risk of meningococcal infections, the complete series for the MenACWY and MenB vaccines should be administered. […] Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

• #9 Meningococcal Meningitis Treatment & Management: Approach Considerations, Pharmacologic Care, Prophylaxis

  https://emedicine.medscape.com/article/1165557-treatment

  Person-to-person transmission can be interrupted by chemoprophylaxis, which eradicates the asymptomatic nasopharyngeal carrier state. […] Deterrence and prevention of meningococcal meningitis can be achieved by either immunoprophylaxis or chemoprophylaxis. Rifampin, quinolones, and ceftriaxone are the antimicrobials that are used to eradicate meningococci from the nasopharynx. […] Vaccination is used for close contacts of patients with meningococcal disease due to A, C, Y, or W135 serogroups, to prevent secondary cases. Current meningococcal vaccines are indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis. […] For routine vaccination, it is recommended that healthy individuals aged 16-23 years receive a 2-dose series, with doses administered 6 months apart, based on shared clinical decision-making. Adults at increased risk for serogroup B meningococcal disease should receive a 3-dose series at intervals of 0, 12, and 6 months.

• #9 Meningococcal Meningitis Treatment & Management: Approach Considerations, Pharmacologic Care, Prophylaxis

  https://emedicine.medscape.com/article/1165557-treatment

  The new recommendations for the use of the MenB vaccine during pregnancy suggest postponing vaccination until after pregnancy, due to insufficient safety data for pregnant individuals. […] Vaccines against meningococcus A, C, W, and Y are available. ACIP guidelines include a recommendation for primary immunization for children aged 11-12 years, with a booster dose at age 16 years. […] Serogroup B vaccine is indicated as a 3-dose series in adolescents and young adults aged 10 through 25 years. College students also benefit from vaccination.

• #10 Immunizations: Meningococcal Vaccines | Wisconsin Department of Health Services

  https://www.dhs.wisconsin.gov/immunization/meningvaccines.htm

  Staying up to date with recommended vaccines is the best protection against meningococcal disease. […] The CDC (Centers for Disease Control and Prevention) recommends meningococcal vaccines for all preteens and teens. In certain situations, other children and adults should get meningococcal vaccines. […] The MenB vaccine prevents infection with meningococcal type B. […] The CDC recommends a MenB vaccine for people ages 16-23 years old, especially those at high risk of meningococcal disease. […] Multiple doses of MenB are needed for the best protection. […] Close contacts of a person with meningococcal disease should receive antibiotics to prevent them from getting sick.

• #11 Meningococcal Disease and the Men B Vaccine | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/meningococcal-disease-vaccine.html

  In June 2015, the U. S. Advisory Committee on Immunizations Practices (ACIP) provided a category B recommendation for both Men B vaccines, making the vaccine appropriate for individual clinical decision-making: […] A serogroup B meningococcal (Men B) vaccine series may be administered to adolescents and young adults 16 through 23 years of age to provide short term protection against most strains of serogroup B meningococcal disease. The preferred age for Men B vaccination is 16 through 18 years of age. […] The ACIP recommends routinely administering Men B vaccines among certain individuals 10 years or older who are at increased risk for serogroup B meningococcal disease. This includes those individuals with complement component deficiencies; anatomic or functional asplenia; microbiologists routinely exposed to isolates of Neisseria meningitides; and those at increased risk because of a serogroup B meningococcal disease outbreak. This is a category A recommendation.

• #11 Meningococcal Disease and the Men B Vaccine | AAFP

  https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/meningococcal-disease-vaccine.html

  FDA approval for the Men B vaccines was granted via an accelerated process, based on 3,000 to 4,000 subjects. Since FDA approval was granted, additional data on more subjects was collected when the vaccines were used during outbreaks on college campuses. […] The ACIP estimates the cost per quality-adjusted life year to be in excess of four million dollars.

• #12 FAQ — American Society for Meningitis Prevention

  https://meningitisprevention.org/faq

  The CDC recommends meningococcal vaccination for all adolescents. The CDC states that all 11-to-12-year-olds should get a meningococcal conjugate (also known as MenACWY vaccine), with a booster dose at 16 years old. Teens and young adults (16 through 23 years old) may also get a MenB vaccine (2-dose series), preferably at 16 through 18 years old. People 10 years or older at increased risk for meningococcal disease should also receive the MenB vaccine. […] The CDCs Advisory Committee on Immunization Practices (ACIP) recommends the MenB vaccine for healthy 16-23-year-olds on the basis of shared clinical decision-making. […] To help protect against ALL vaccine-preventable groups of meningitis, ensure you are vaccinated against ALL 5 types of meningococcal bacteria most likely to cause meningococcal meningitis: ABCWY.

• #12 FAQ — American Society for Meningitis Prevention

  https://meningitisprevention.org/faq

  For both Bexsero and Trumenba, more than one dose is required for maximum protection. A 2-dose series is required for people aged 16-23 who are not at an increased risk of meningococcal disease administered six months apart. For people aged 10 years and older at increased risk of Meningitis B, the ACIP recommends that 3 doses of Trumenba or Bexsero be administered at 0, 12, and 6 months. […] Yes! Some providers recommend that 16-year-olds receive the first dose of the MenB vaccine at the same time that they receive the second dose of the MenACWY vaccine. An alternative to receiving both the MenACWY and the MenB vaccine at the same visit is receiving the MenABCWY vaccine. If receiving the MenABCWY vaccine, a second MenB vaccine will need to be administered 6 months later.

• #13 Meningococcal Disease and the Vaccine: What College Students Need to Know – MN Dept. of Health

  https://www.health.state.mn.us/diseases/meningococcal/collegefact.html

  Anyone can get meningococcal disease, but first-year college students who live in dormitories or participate in sororities or fraternities are at increased risk and should get vaccinated. […] Vaccination is one of the most effective ways to prevent meningococcal disease. […] The meningococcal B vaccine (MenB) can be given to people aged 16-23 years. MenB vaccine is also recommended for people over age 10 years with certain high-risk conditions. […] It is important for students ages 16 to 23 who are planning to go to college or currently in college, to have a conversation with their health care provider about receiving the MenB vaccine. Anyone who has been fully vaccinated against MenB, would only need a single booster dose in the case of an outbreak on campus.

• #14 Meningitis | Student Health Center | Western Washington University

  https://studenthealth.wwu.edu/meningitis

  Based on the possibility of increased risk, students entering Western are advised to strongly consider the Meningococcal vaccine as a way to reduce their risk for potentially fatal Meningococcal disease. […] Two separate meningitis vaccines are necessary to be fully immunized against the disease: MenACWY and MenB. While many adolescents and young adults have received the MenACWY vaccine as part of their regular immunizations, few have received the MenB vaccine. […] Meningococcal disease strain B, commonly referred to as MenB, is the most common cause of bacterial meningitis on college campuses. The Centers for Disease Control and Prevention recommend being vaccinated against meningitis B. […] Make sure you have BOTH meningitis vaccines to fully protect yourself and those around you. […] We urge you to strongly consider vaccination with your health care provider, local health department or here at the Student Health Center. […] The MenB vaccine is available at most pharmacies. Check with your health insurance carrier to see if it is covered.

• #15 Meningococcal Vaccine Recommendations | Meningococcal | CDC

  https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html

  CDC recommends a shared clinical decision-making process to decide if MenB vaccination is appropriate for individual adolescents or young adults. […] Administer 2 doses, 6 months apart, to those who want MenB vaccination. […] In certain situations, individuals ages 10 years and older should receive a 3-dose primary series. […] CDC recommends a booster dose for these individuals if a year or more has passed since the most recent MenB vaccine.

• #16 MenB Information | Student Affairs and Campus Diversity | SDSU

  https://sacd.sdsu.edu/health-promotion/healthier-you/menb

  Fully immunized means having received all doses required for the MenB vaccination, a multi-dose series. […] Immunization is still recommended for all of those ages 23 and younger who received Cipro (ciprofloxacin) due to possible exposure as a close contact in early September. […] There are two available vaccines for serogroup B meningococcal disease; Bexsero (a two-dose series) and Trumenba (a three-dose series during outbreaks). […] Both MenB vaccines are administered through an intramuscular injection in the arm. […] The Centers for Disease Control and Prevention reports that potential side effects from receiving the MenB vaccine can include soreness, redness and swelling around the area where the shot was given; feeling tired; headaches; muscle or joint pain; fever or chills; nausea or diarrhea.

• #16 MenB Information | Student Affairs and Campus Diversity | SDSU

  https://sacd.sdsu.edu/health-promotion/healthier-you/menb

  San Diego State University is continuing its efforts to support the health and safety of the university community. […] SDSU is asking all students 23 years of age and younger to check their immunization records and to get vaccinated for MenB a potentially fatal disease spread through close contact with those who are ill. […] The effective vaccines for MenB are Trumenba and Bexsero, which were approved by the FDA in 2014-15. […] MenB is life-threatening. Prompt diagnosis and treatment is critical because the disease progresses rapidly and can be fatal in as few as 12 hours after symptoms that often resemble influenza. […] The best prevention is vaccination. The two vaccines that are most effective against MenB are Bexsero and Trumenba. […] All San Diego State University undergraduate students ages 23 and younger who have not been fully immunized with the meningococcal B (MenB) vaccine are urged to get vaccinated as soon as possible.

• #16 MenB Information | Student Affairs and Campus Diversity | SDSU

  https://sacd.sdsu.edu/health-promotion/healthier-you/menb

  If you have started one of the MenB vaccine series (Bexsero or Trumenba), make plans to complete the appropriate series through your health-care provider or a convenient pharmacy at the correct time interval. […] Students may only request medical exemptions. […] Medical exemptions are for students unable to receive vaccines due to health risks. […] Individuals should avoid the vaccine if they have had any severe, life-threatening allergic reaction to a previous dose of MenB vaccine or if they have a severe allergy to any part of this vaccine.

• #17 HCP Site | TRUMENBA® (Meningococcal Group B Vaccine) | Safety Info

  https://trumenba.pfizerpro.com/

  After the October 2024 ACIP vote, all MenB vaccines now align to the same schedule (2 doses at 0 and 6 months when used as a 2-dose series) for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making. […] TRUMENBA has demonstrated coverage against diverse MenB strains by covering both subfamilies A and B of fHbp. […] TRUMENBA is proven to help protect against diverse MenB strains, which is important because you don’t know which of the 1800 MenB strains your patients may encounter. […] TRUMENBA offers proven protection with a 2-dose schedule. […] ONLY TRUMENBA covers both subfamilies of fHbp, A B, that have been found on 99% of MenB disease-causing strains, as well as strains that have caused MenB outbreaks at US colleges. […] MenB vaccination is part of the CDC 16-year-old vaccination platform.

• #18 Meningococcal Vaccines – Medical Clinical Policy Bulletins | Aetna

  https://www.aetna.com/cpb/medical/data/300_399/0356.html

  Aetna considers meningococcal vaccines, meningococcal conjugate (MenACWY) vaccine (e.g., Menactra, Menveo, and MenQuadfi), serogroup B meningococcal (MenB) vaccine (Bexsero and Trumenba), and meningococcal conjugate (MenABCWY) vaccine (e.g., Penbraya) as a medically necessary preventive service according to the recommendations of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP). […] ACIP recommends routine vaccination of persons aged 10 years or older at increased risk for meningococcal disease (dosing schedule varies by vaccine brand; boosters should be administered at 1 year after primary series completion, then every 2 – 3 years thereafter). […] MenB vaccination is not routinely recommended for all adolescents. Instead, ACIP recommends a 2-dose MenB series for persons aged 16 to 23 years on the basis of shared clinical decision-making, which refers to an individually based vaccine recommendation informed by a decision-making process between the health care provider and the patient or parent/guardian. The preferred age for MenB vaccination is 16 to 18 years. Booster doses are not recommended unless the person becomes at increased risk for meningococcal disease (Mbaeyi et al, 2020).

• #19 Meningitis B Prevention Update: A Case-based Focus on the At-risk Demographic of Young Adults

  https://dxlink.ca/CJDX/2019/May/MenB_Prevention_Update.html

  There are currently two vaccines available for protection against MenB (Bexsero and TrumenbaTM). […] The multi-component MenB vaccine, Bexsero, is indicated for the active immunization of individuals aged 2 months to 25 years against IMD caused by MenB. […] The safety and immunogenicity profile of this vaccine is based on data from 15 clinical studies, four of which were phase 3 studies that included adolescents and/or young adults. […] Overall, the clinical trials demonstrated that Bexsero induced a robust immune response against MenB test strains following this two-dose vaccine schedule. […] The other vaccine against invasive MenB disease, Trumenba, is a bivalent vaccine comprised of two recombinant lipidated fHBP variants and is indicated for active immunization to prevent IMD caused by MenB in individuals aged 10-25 years.

• #19 Meningitis B Prevention Update: A Case-based Focus on the At-risk Demographic of Young Adults

  https://dxlink.ca/CJDX/2019/May/MenB_Prevention_Update.html

  The immunogenicity and safety of Trumenba has been evaluated in 11 clinical trials involving more than 20,000 subjects. […] Overall, the vaccine showed robust immune responses in both age groups (10-18 years and 18-25 years), as 80% had the predefined response. […] For patients at increased risk of IMD, a three-dose schedule is recommended, with the second dose given at least one month after the first, and the third dose given four months after the second. […] Both available MenB vaccines have demonstrated robust immunogenicity profiles against circulating strains of MenB.

• #20 Clinical Guidance for Managing Meningococcal Disease Risk in Patients Receiving Complement Inhibitor Therapy | Meningococcal | CDC

  https://www.cdc.gov/meningococcal/hcp/clinical-guidance/complement-inhibitor.html

  CDC recommends both MenACWY and MenB vaccines for people receiving a complement inhibitor. Ideally, complete or update meningococcal vaccination at least 2 weeks prior to administering the first dose of the complement inhibitor. However, patients can initiate complement inhibitor therapy before meningococcal vaccination has been completed if the risks for delaying complement inhibitor therapy outweigh the risks for developing meningococcal disease. […] MenB vaccines require 3 doses. […] Administer a booster dose of MenB vaccine: 1 year after series completion; Every 2 to 3 years thereafter, for the duration of complement inhibitor therapy. […] Targets: Serogroup B; cross protection against nongroupable N. meningitidis hasn’t been systematically assessed.

• #21 Schedule Meningitis Vaccine (Meningococcal) | Walgreens

  https://www.walgreens.com/topic/pharmacy/scheduler/meningitis-vaccine_37.jsp

  MenB vaccination is recommended for: […] For individuals 10 years or older at increased risk for serogroup B meningococcal disease should receive a 3 dose primary series with a booster 1 year after series completion and every 2-3 years thereafter.

• #22 Meningococcal Vaccine: Protection, Risk, Schedule

  https://www.verywellhealth.com/meningococcal-vaccine-5215620

  Fortunately, a vaccine can protect against this disease and its more serious consequences. The meningococcal vaccine can help protect against different versions of disease caused by Neisseria meningitidis. […] Another type of meningococcal vaccine is the MenB vaccine, which protects against a fifth strain of Neisseria meningitidis. In the U.S., parents can opt to give their children a MenB vaccine once they’re in their teens. […] The CDC’s analysis of the efficacy of the MenB vaccines in the real world comes from studies done in other countries. In Canada, a study followed a mass vaccination campaign in a region with a meningitis B outbreak and found that a MenB vaccine was 79% effective in the four years after vaccination. […] By 2018 as many as 92% of eligible infants in the UK completed a MenB vaccination by their first birthday, according to a 2020 study in The New England Journal of Medicine. […] The study noted a 75% drop in cases among vaccine-eligible age groups, compared to the expected numbers.

• #23

  https://www.meningitis.org/blogs/menb-gonorrhoea-and-vaccines

  There is growing evidence to suggest that vaccines licensed to protect against meningitis and septicaemia, caused by meningococcal group B (MenB) infection, can also offer some protection against gonorrhoea. […] MenB vaccines have been shown to be highly successful in protecting vaccinated populations in England from MenB. […] These findings show that, two years after the introduction of childhood and adolescent MenB vaccination programmes in South Australia, there was a 60% reduction in incidence of MenB disease in infants aged 12 weeks to 11 months, and a 73% reduction in 15-18 year olds compared to the levels that would be expected with no vaccine in place. […] The MenB vaccine Bexsero also provides moderate cross-protection against gonorrhoea. Receiving two doses of Bexsero, which includes an OMV component, is estimated to reduce the chances of getting gonorrhoea by 33%.

• #23

  https://www.meningitis.org/blogs/menb-gonorrhoea-and-vaccines

  Similar potential effects have also since been seen in Canada and the United States. […] The analyses from this study revealed that gonorrhoea rates were 46% lower among recipients of Bexsero vs. the MenACWY vaccine, which led the authors to conclude, that OMV-based meningococcal vaccines may be a potential tool for gonorrhoea control. […] The potential for Bexsero to offer protection against gonorrhoea, as well as meningitis, has important implications for measuring the cost-effectiveness of future MenB vaccination programmes in the UK. […] Even with a relatively modest vaccine effectiveness against gonorrhoea, the potential implications are substantial given that in 2020 the World Health Organization (WHO) estimated there were 82 million new cases of gonorrhoea. […] It is therefore promising for both wider meningitis protection and protection against gonorrhoea that a new modelling study which explored the effectiveness of different vaccination strategies in protecting men who have sex with men (MSM) against gonorrhoea has found that immunising higher risk MSM could be hugely cost saving to the NHS. […] These recent finding, not only support the continuation of the MenB vaccination programme in South Australia to protect infants and adolescents against two diseases with one vaccine, but provide essential data to support the wider use of Bexsero elsewhere.

• #24 Meningococcal Group B Vaccine For The Prevention Of Invasive Meningoco | IDR

  https://www.dovepress.com/meningococcal-group-b-vaccine-for-the-prevention-of-invasive-meningoco-peer-reviewed-fulltext-article-IDR

  The genes encoding for the antigens fHbp, NHBA, and NadA can be present and expressed in other serogroups, suggesting a potential impact of MenB vaccines against non B strains. […] The results showed that sera of 4CMenB immunized subjects induced complement-mediated killing of MenC, MenW, and MenY in a range from 45% to 90%, suggesting that 4CMenB vaccine could potentially have an impact on non-B meningococcal disease. […] The potential for MenB vaccines to prevent infection by non-B serogroups appears promising, and the impact on other pathogenic Neisserial species with homologous surface proteins warrants further investigation. […] Overall, with the remaining burden of invasive meningococcal disease across Europe and other parts of the world, mostly of serogroup B meningococcus, new vaccines should highly be considered for broad use.

• #25 Exploring a Meningitis Vaccine for Gonorrhea Prevention | NIAID: National Institute of Allergy and Infectious Diseases

  https://www.niaid.nih.gov/news-events/meningitis-vaccine-gonorrhea-prevention

  A preventive vaccine for gonorrhea would be a major advance in public health, according to an editorial co-authored by NIAID Director Jeanne Marrazzo, M.D., M.P.H, and Myron Cohen, M.D., director of the Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill. […] The genetic sequences of N. gonorrhoeae and Neisseria meningitidis group B, the bacteria that can cause meningitis B, are closely related, which have led researchers to explore whether the 4CMenB vaccine, approved by the Food and Drug Administration for meningitis B, might also prevent gonorrhea. […] NIAID is sponsoring an efficacy study of the 4CMenB vaccine for gonorrhea prevention in more than 2,000 people aged 18-50 years in Malawi, Thailand, and the United States. […] The model projected how the dosing, vaccine effectiveness, health promotion, and availability for those most likely to benefit could affect the cost effectiveness of 4CMenB vaccination for gonorrhea, showing a potential benefit even if efficacy is low in forthcoming study results.

• #26 Routinely offer MenB jabs to prevent gonorrhoea, UK vaccine committee recommends | The BMJ

  https://www.bmj.com/content/383/bmj.p2696

  The Joint Committee on Vaccination and Immunisation (JCVI) has advised the UK government that meningococcal B (MenB) vaccines should be routinely offered to prevent gonorrhoea by targeting the people at greatest risk. […] Evidence indicates that, even with a modest vaccine effectiveness against gonorrhoea of 32.7-42.0%, rolling out the 4CMenB vaccine to groups with the highest risk could prevent many cases, said the committee.

• #27

  https://www.gov.uk/government/publications/meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea-jcvi-advice-10-november/jcvi-advice-on-the-use-of-meningococcal-b-vaccination-for-the-prevention-of-gonorrhoea

  The JCVI considered the evidence presented in terms of programme cost-effectiveness and likely impact on gonorrhoea epidemiology. The committee agreed that a targeted programme should be initiated using the 4CMenB vaccine for the prevention of gonorrhoea in those who are at greatest risk of infection. […] It is important for individuals offered vaccination to understand that real world studies have estimated that the 4CMenB vaccine has between 32.7 to 42% effectiveness against gonorrhoea. Therefore, although vaccination would be expected to reduce the chance of becoming infected with gonorrhoea, it would not completely eliminate the possibility. Vaccinated individuals could expect to have some reduction in their own risk of contracting gonorrhoea, however the main benefit of a vaccination programme is expected to be at a community level with a significant reduction in the number of cases overall. […] As protection against gonorrhoea isnt currently a licensed indication for 4CMenB vaccine, this advice is based on off-label use of vaccine.

• #28 ZILBRYSQ® Vaccination Schedule

  https://www.zilbrysqhcp.com/vaccination

  Complete or update meningococcal vaccination (for serogroups A, C, W, Y, and B) at least 2 weeks prior to administration of the first dose of ZILBRYSQ, according to current ACIP recommendations for patients receiving a complement inhibitor. […] If urgent ZILBRYSQ therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. […] The benefits and risks of antibiotic prophylaxis for prevention of meningococcal infections in patients receiving ZILBRYSQ have not been established. […] The optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including ZILBRYSQ.

• #29 Meningitis and Meningitis Vaccination Information

  https://www.steu.edu/student-life/wellness-center/health-services/meningitis.html

  Two meningococcal vaccines (MenACWY and MenB) provide protection against the serogroups that cause most meningococcal disease in the United States. […] The Meningitis vaccine that is required for the traditional undergraduates and residents is Meningitis ACWY, it does not protect against Meningitis B. […] Get protected against meningitis B get vaccinated! Call Health Services or your doctor. […] Providers, college students, and parents should be aware of the availability of MenB vaccines. […] Close contacts of someone with meningococcal disease should receive antibiotics to help prevent them from getting the disease. This is known as prophylaxis (pro-fuh-lak-sis). […] Vaccines help protect against all three serogroups (B, C, and Y) of Neisseria meningitidis bacteria commonly seen in the United States. […] Teens and young adults (16 through 23 year olds) also may be vaccinated with a serogroup B meningococcal vaccine. […] Close contacts of a person with meningococcal disease should receive antibiotics to prevent them from getting sick. This is known as prophylaxis (pro-fuh-lak-sis).

• #30 Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY | GSK

  https://www.gsk.com/en-gb/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/

  GSKs MenB vaccine has received regulatory approval in over 55 countries, including the US, and is used in 18 national immunisation programmes worldwide for the prevention of IMD caused by Neisseria meningitidis serogroup B. More than 110 million doses have been distributed worldwide since 2015. It is supported by clinical data supporting its effectiveness in helping to protect adolescents and young adults against diverse disease-causing strains of MenB, with a well-characterised safety profile. In the US, this vaccine has received regulatory approval for active immunisation to prevent invasive disease caused by Neisseria meningitidis serogroup B and is approved for use in individuals aged 10 through 25 years. […] GSKs MenABCWY vaccine is an injectable suspension for intramuscular use. The vaccine is supplied as one vial of lyophilized MenACWY Component (powder) which is reconstituted at the time of use with the accompanying prefilled syringe of MenB Component (liquid). It is indicated in the US for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y. It is approved in the US for use in individuals aged 10 through 25 years.

• #31

  https://www.nhs.uk/conditions/meningitis/vaccination/

  Meningitis can be caused by a number of different infections, so several vaccinations offer some protection against it. […] The MenB vaccine offers protection against meningococcal group B bacteria, which are a common cause of meningitis in young children in the UK. […] The vaccine is recommended for babies aged 8 weeks, followed by a second dose at 16 weeks and a booster at 1 year.

• #32 Meningococcal vaccine | Caring for kids

  https://caringforkids.cps.ca/handouts/immunization/meningococcal_vaccine

  Meningococcal B vaccine (Men-B) protects children against type B. This vaccine is not given routinely but is usually given to children at higher risk of getting meningococcal disease. […] Children at higher risk for meningococcal disease (children with no spleen or who have certain medical conditions) should receive MCV-4 and Men-B vaccine starting as early as 2 months of age. […] Currently, no provinces or territories cover the cost of Men-B vaccine for all children. Some provide it for children at high risk of getting meningococcal disease.

• #33 Vaccine Scheduler | ECDC

  https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1

  Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. […] Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. […] Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. […] Introduction of MenB vaccine in January 2025.

• #34 The Medical Letter Home Page | The Medical Letter, Inc.

  https://secure.medicalletter.org/TML-article-1726a

  The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. […] Pentavalent vaccination is recommended only for persons 10 years old who would otherwise have received both a MenACWY and a MenB vaccine at the same visit. […] Use of Penmenvy or Penbraya reduces the total number of injections required for full vaccination against these five serogroups, which may improve compliance.

• #35 Navigating the Changing Meningitis Vaccine Landscape: Dosing Guidance and New Developments

  https://www.unity4teenvax.org/resource/navigating-the-changing-meningitis-vaccine-landscape-dosing-guidance-and-new-developments/

  The MenB vaccine should be administered preferably between 16 and 23 years old. Many teens have yet to receive the meningococcal group B vaccine. Its uptake remains low as only 31.4% had received more than 1 MenB dose in 2021. […] Together these two vaccines play a key role in preventing meningococcal disease. […] Yes, its possible that your adolescent is due for the MenACWY booster dose and the first MenB dose at age 16. If so, they can get one dose of MenABCWY vaccine instead. Note that for protection against serogroup B, a second dose of the MenB vaccine is still required. […] Yes. That said, its important to make sure that your adolescent gets the same vaccine brand for all doses of MenB vaccine. If your child receives MenABCWY vaccine, which includes the MenB vaccine Trumenba, then they need to get Trumenba for their second MenB dose. […] If your adolescent is 16 years old or older, they might be a good candidate for the MenABCWY vaccine. If they are younger, we encourage you to speak with your provider about your options.

• #36 Vaccine-Based Prevention of Meningococcal B Disease: Tools for Interpreting and Implementing Recommendations | myCME

  https://www.mycme.com/courses/vaccine-based-prevention-of-meningococcal-b-disease-tools-for-interpreting-and-implementing-recommendations-7609

  Meningococcal disease, specifically serotype B (MenB), is an ongoing problem in this country. The disease can develop from initial symptoms to death within 24 hours. Given how disabling this disease can be it is essential health care workers, who deliver vaccinations, enhance their standards of care in practice in order to deliver the highest rates of preventative care in this area. The goal of the activity is to improve comprehension and initiate practice changes so as to improve immunization rates for all patients who are currently scheduled for the MenB vaccination. […] At the conclusion of this activity, participants should be able to: […] Utilizing case-based video vignettes, implement strategies to improve uptake of meningococcal B vaccine in clinical practice.

• #37 JCVI advises on gonorrhoea and mpox vaccinations – GOV.UK

  https://www.gov.uk/government/news/jcvi-advises-on-gonorrhea-and-mpox-vaccinations

  The JCVI’s advice on gonorrhoea says that a targeted vaccination programme should use the 4CMenB vaccine for the prevention of gonorrhoea. […] Meningococcal disease (Neisseria meningitidis) and gonorrhoea (Neisseria gonorrhoeae) are closely genetically related, with evidence showing that MenB vaccine provides some cross-protection against gonorrhoea. […] In reviewing the evidence, the JCVI noted that even with the modest vaccine documented effectiveness against gonorrhoea (between 32.7% to 42%) many cases of gonorrhoea could be prevented. […] While the main benefit of a vaccination programme is expected to be at a community level with a significant reduction in the number of cases overall, vaccinated individuals could expect to have some reduction in their own risk of contracting gonorrhoea.

• #38 American Society for Meningitis Prevention

  https://meningitisprevention.org/

  Meningococcal meningitis can be deadly. But there is something you can do about it. Make sure you are not missing any of the vaccines needed to help prevent it. […] Because meningococcal meningitis is mainly caused by 5 types of meningococcal bacteria – ABCWY – ensure you are not missing any of the vaccines needed to help prevent it. […] Join our incredible community of advocates helping us increase awareness of all vaccines available to help prevent meningococcal meningitis in their communities.

• #39 Infectious Disease Prevention | Student Wellbeing | Division of Student Life | University of Delaware

  https://www.udel.edu/students/health-wellbeing/medical-services/infectious-disease-prevention/

  Students: Meningitis ACWY vaccine is available at SHS. Please call 302-831-2226 to make an appointment. In an emergency, always dial 911. Please note that this vaccine is not covered by the UD Wellbeing Fee but the cost can be billed to insurance. Meningitis B vaccines are available at local pharmacies. […] The vaccines for meningococcal serogroups A, C, W and Y (MenACWY; Menactra, Sanofi Pasteur; Menveo, GlaxoSmithKline [GSK]; MenQuadfi, Sanofi Pasteur) contain meningococcal conjugate in which the surface polysaccharide is chemically bonded (conjugated) to a protein to produce a robust immune response to the polysaccharide. […] Since late 2014, vaccines have become available that offer protection from meningococcal serogroup B disease (MenB; Bexsero, GSK; Trumenba, Pfizer). These vaccines are composed of proteins found on the surface of the bacteria. […] MenACWY vaccines provide no protection against serogroup B disease, and meningococcal serogroup B vaccines (MenB) provide no protection against serogroup A, C, W or Y disease. For protection against all five serogroups of meningococcus, it is necessary to receive both MenACWY and MenB.

Zobacz więcej